SCHEMBL921265

SCHEMBL921265

O=C(O)CON=C1c2ccccc2-c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.65
MAPK9 P45984 2/20 0.65
MAPK10 P53779 2/20 0.65
LMNA P02545 5/20 0.61
HPGD P15428 4/20 0.59
HTT P42858 4/20 0.59
MAPT P10636 3/20 0.59
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 6/20 0.51
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALOX15 P16050 1/20 0.44
ADRB1 P08588 3/20 0.43
RAD52 P43351 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL921331 0.81 LMNA (0.50) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL14193659 0.81 LMNA (0.54) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL10556400 0.80 MAPK8 (0.52) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL23752301 0.75 LMNA (0.51) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL23752300 0.75 LMNA (0.51) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL8381142 0.71 LMNA (0.54) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL515790 0.70 IDO1 (0.51) MAPK8MAPK9MAPK10LMNAHPGD
SCHEMBL16473372 0.69 KMT2A (0.44) MAPK8MAPK9MAPK10LMNAMAPT
SCHEMBL31667881 0.69 ALDH1A1 (0.57) HPGDHTTMAPTALDH1A1MEN1
SCHEMBL10164638 0.69 ALDH1A1 (0.57) HPGDHTTMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8779138-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2014-07-15 US disclosed
US-8779138-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2014-07-15 US disclosed
US-8779138-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2014-07-15 US disclosed
US-8563537-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2013-10-22 US disclosed
US-8563537-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2013-10-22 US disclosed
US-8563537-B2 Camptothecin derivatives as chemoradiosensitizing agents Sutter West Bay Hospital (US) 2013-10-22 US disclosed
EP-1951231-B1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MED CENTER (US) 2013-07-31 EP disclosed
EP-1951231-B1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MED CENTER (US) 2013-07-31 EP disclosed
US-20110184009-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER 2011-07-28 US disclosed
US-20110184009-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER 2011-07-28 US disclosed
US-7875602-B2 Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic SUTTER WEST BAY HOSPITALS (US) 2011-01-25 US disclosed
US-20080318873-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MEDICAL CENTER 2008-12-25 US disclosed
US-20080318873-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MEDICAL CENTER 2008-12-25 US disclosed
US-20080318873-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MEDICAL CENTER 2008-12-25 US disclosed
EP-1951231-A2 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS California Pacific Medical Center (US) 2008-08-06 EP disclosed
WO-2007048002-A2 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MEDICAL CENTER (US) 2007-04-26 WO disclosed
WO-2007048002-A2 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS CALIFORNIA PACIFIC MEDICAL CENTER (US) 2007-04-26 WO disclosed
US-20070093432-A1 Camptothecin derivatives as chemoradiosensitizing agents CALIFORNIA PACIFIC MEDICAL CENTER 2007-04-26 US disclosed
US-20070093432-A1 Camptothecin derivatives as chemoradiosensitizing agents CALIFORNIA PACIFIC MEDICAL CENTER 2007-04-26 US disclosed
US-20070093432-A1 Camptothecin derivatives as chemoradiosensitizing agents CALIFORNIA PACIFIC MEDICAL CENTER 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093432-A1 Camptothecin derivatives as chemoradiosensitizing agents ERCC2, CHEK1, ERCC4 MAPK8 1985/4885MAPK9 2549/4885MAPK10 2207/4885
US-20110184009-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS ERCC2, CHEK1, ERCC4 MAPK8 1985/4885MAPK9 2549/4885MAPK10 2207/4885
US-20080318873-A1 CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS ERCC2, CHEK1, ERCC4 MAPK8 1985/4885MAPK9 2549/4885MAPK10 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.